Twenty years ago, clinical trials operated like locked boxes. Researchers wrote the protocols. Participants followed directions. Guideline panels were the domain of experts in white coats, speaking a language most people couldnāt understand. The very individuals most affected by these decisionsāpeople living with chronic conditionsāwere rarely invited to the table.
That world is changing. Slowly in some places, rapidly in others. As someone who has lived with chronic pain for decades and now advises on clinical trials and health guidelines, I want to unpack whatās changed, whatās still shifting, and where we must go next to make research truly serve the people itās meant to help.
š Clinical Trials: 20 Years Ago
Back in the early 2000s, clinical trials were highly structured and tightly controlled:
- Randomized Controlled Trials (RCTs) were the only real option.
- Participants were called āsubjectsāārarely engaged as partners.
- Trial designs didnāt reflect the messiness of real life, especially for those with multiple or chronic conditions.
- Data was mostly paper-based, and recruitment was often slow and unrepresentative.
- Little effort was made to include diverse populations.
Guideline panels mirrored that same narrow lens. Clinicians and researchers dominated discussions. Recommendations were developed about patientsābut almost never with them. There were no plain-language summaries, no transparency about conflicts of interest, and no attention to whether the recommendations were actually workable in real-world life.
š Clinical Trials Today
Today, the research landscape looksāand feelsādifferent:
- Trial designs are more flexible and real-world-friendly: adaptive, pragmatic, and decentralized models are increasingly common.
- Many studies now actively include people with lived experience (PWLE) in the design and governance of trials.
- Patients and caregivers help review consent forms, develop recruitment materials, and define what outcomes matter.
- Digital tools like wearables, apps, and telehealth make participation more accessible and inclusive.
- There is a growing recognition that real-world evidence (RWE) adds depth to traditional RCTs.
Guideline development is also transforming:
- Panels increasingly include PWLE as voting members, not just token observers.
- Tools like GRADE now integrate the values, preferences, and lived realities of patients into how evidence is weighed.
- Organizations such as PCORI, NIH, and FDA have developed frameworks that require meaningful engagement throughout the research and policy process.
Still, challenges persist. Representation remains uneven. Engagement can still be superficial. And in many spaces, āpatient voiceā is more performance than partnership.
š® Looking Ahead: The Future of Research and Guidelines
The future of research should be built with us, not just for us. Hereās where weāre headingāand where we must insist on going:
ā Clinical Trials of the Future:
- PWLE as co-leaders, not just consultants, from protocol design to data interpretation and dissemination.
- Growth in personalized medicine trials using biomarker and genomic data.
- Trials that are decentralized by default, using remote monitoring and community-based partnerships.
- Smart use of AI and machine learning to improve recruitment, retention, and equity.
- Immersive tools like AR/VR to enhance informed consent and participant education.
š Future of Guideline Panels:
- Co-production of guidelines with PWLE and front-line healthcare workers.
- Living guidelines that are continuously updated in response to new data and evolving community needs.
- Clear, accessible summaries that support informed decision-making by patients, caregivers, and clinicians.
- Panels held accountable for equity, inclusion, and real-world applicabilityānot just academic rigor.
š¬ Why This Matters
Iāve sat in both chairsāperson living with pain, and advisor on research and policy teams. I know what itās like to feel invisible. I also know the power of being heard and having your knowledge valued.
This isnāt just about fairnessāitās about better outcomes. Trials and guidelines are more effective, more trusted, and more widely adopted when people with lived experience help shape them. Engagement isnāt a luxuryāitās a necessity for good science.
š What We Can Do Now
- Demand co-leadership roles for PWLE at every stage of the research lifecycle.
- Use tools like the PCORI Engagement Rubric to evaluate the depth of engagement.
- Invest in training and mentoring PWLE so they can participate confidently and effectively.
- Ask tough questions: Whoās at the table? Whoās not? And why?
š Resources
- PCORI Engagement Rubric: https://www.pcori.org/sites/default/files/Engagement-Rubric.pdf
- FDA Patient-Focused Drug Development: https://www.fda.gov/drugs/development-approval-process-drugs/fda-patient-focused-drug-development-guidance-series-enhancing-incorporation-patients-voice-medical
- Clinical Trials Transformation Initiative (CTTI): https://www.ctti-clinicaltrials.org/
- GRADE Working Group: https://www.gradeworkinggroup.org/